Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects

David A. Loeffler
ISSN / E-ISSN
— / —
DOI
10.3233/adr-230025 ↗
Volume · Issue · Pages
7 · 1 · 873-899
Publisher
IOS Press BV
Article URL
https://doi.org/10.3233/adr-230025 ↗
Article details
Unverified
Publication date (each date has its type and source)
07 Aug 2023
OpenAlex publication date · source: OpenAlex
Dates on record for this article
TypeDateSource
OpenAlex publication date07 Aug 2023 OpenAlex

Keywords (as given): Alzheimer's disease; amyloid-beta clearance; anti-amyloid monoclonal antibodies; aducanumab; lecanemab; donanemab; intravenous immunoglobulin; microglial phagocytosis; complement activation; tau aggregation; amyloid hypothesis; immunotherapy

HEC Status at Publication Not the journal's current status

HEC Status at PublicationConclusive
HEC status at publication Recognized
Based on the recorded HEC dataset applicable to the article's publication date. Listed in the HEC list for 2023–24.
Journal
Journal of Alzheimer's Disease Reports
Publication date used
07 Aug 2023 (OpenAlex publication date)
Applicable HEC period
2023–24 (version 1) · 01 Jul 2023 – 30 Sep 2024
Category
—
Recognition status
Recognized (OK_RECORD_FOUND)
Source
HJRS 2023-24 page 2200, row 15501
Verification status
Verified against source · last verified 23 Sep 2026
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.